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Increased Intratumoral FOXP3-positive Regulatory Immune Cells
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Abstract Purpose: The administration of interleukin-2 (IL-2) may increase the frequency of peripherally
circulating FOXP3-positive regulatory immune cells, thus potentially compromising this treatment
option for patients withmetastatic renal cell carcinoma.The impact of IL-2^ based therapy on the
accumulation of FOXP3-positive immune cells in the tumor microenvironment in metastatic renal
cell carcinoma is unknown.
Experimental Design: Baseline (n = 58) and on-treatment (n = 42) tumor core biopsies were
prospectively obtained from patients with clear cell metastatic renal cell carcinoma before and
during IL-2^ based immunotherapy. Immunohistochemical expression of FOXP3 was estimated
by stereological counting technique and correlated with other immune cell subsets and overall
survival.
Results: A significant increase in absolute intratumoral FOXP3-positive immune cells was
observed comparing baseline (median 23 cells/mm2; range, 0-183) and on-treatment biopsies
(median, 89 cells/mm2; range, 11-388; P < 0.001).The relative increase in individual patients was
median 4.7-fold, range 0.3 to 230. FOXP3-positive cells were positively correlated with CD3-
positive, CD4-positive, and CD8-positive tumor-infiltrating immune cells at baseline and during
treatment (P < 0.05 in all comparisons). All patients achieving high numbers (>180 cells/mm2) of
on-treatment FOXP3-positive intratumoral immune cells were dead within 22 months (n = 11),
whereas patients with low numbers (<180 cells/mm2) of on-treatment FOXP3-positive cells
(n = 31) had a 5-year survival rate of 19% (hazard ratio, 2.2; confidence interval, 1.03-4.5;
P = 0.043). All long-term survivors were characterized by low-baseline FOXP3-positive cells
and a modest absolute rise in FOXP3-positive cells.
Conclusion: Intratumoral FOXP3-positive regulatory immune cells significantly increased during
IL-2^ based immunotherapy, and high numbers of on-treatment FOXP3-positive cells were
correlated with poor prognosis in patients with metastatic renal cell carcinoma.
Regulatory T cells are highly specialized subsets of immune
cells capable of preventing autoimmunity and limiting immune
reaction in infectious diseases (1). Because most tumor-
associated antigens are predominantly self-antigens, regulatory
T cells may also play a role in preventing an effective
antitumoral immune response (2–5). Increased frequencies
of regulatory T cells have been reported in solid cancers of
lung(6), ovary (4, 6), breast (7, 8), pancreas (8), melanoma
(9, 10), gastrointestinal (11), gastric (12, 13), esophageal (12,
13), head and neck (14), hepatocellular carcinoma (15), and
renal cell carcinoma (16, 17). For these cancers, there seems to
be a correlation between elevated levels of regulatory T cells and
impaired overall survival (18). Regulatory T cells have
traditionally been characterized by the CD4-positive CD25-
positive phenotype, but a novel transcription factor, FOXP3,
is considered a better marker for quantification of regulatory
T cells (19, 20).
Interleukin-2 (IL-2) is the only curative treatment option for
selected patients with metastatic renal cell carcinoma (21).
During the past 20 years, reproducible durable tumor
regressions have been noted after systemic administration of
IL-2 in patients with metastatic renal cell carcinoma, but only in
a minority of patients (22, 23). IL-2 activates several immune
cells including T cells (24), natural killer (NK) cells (25), B cells
(26), monocytes/macrophages (27), and neutrophils (28).
However, recent studies have shown the administration of
IL-2 to cancer patients to be accompanied by an increase in
peripheral circulating FOXP3-positive immune cells, thereby
potentially compromising the establishment of an effective
antitumor immune response due to the induction of opposing
immune cell functions (29–33).
The present study is the first study to assess intratumoral
FOXP3-positive regulatory cells in patients with metastatic renal
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cell carcinoma before and during IL-2–based immunotherapy.
We report that intratumoral FOXP3-positive immune cells
increased in the majority of patients during IL-2 therapy, and
that high numbers of FOXP3-positive cells were associated with
poor overall survival.
Material andMethods
Patient population. Paraffin-embedded tumor biopsies were
collected among a cohort of 120 consecutive patients receiving
IL-2–based immunotherapy in prospective phase II trials using
low- or intermediate-dose s.c. IL-2 (34). Low-dose regimens
consisted of one priming week of daily IFN-a, followed
by cycles of 4 wk with IFN-a (3 mIU  1 s.c) 7 d/wk and
IL-2 (2.4 mIU/m2  2) 5 d/wk, weeks 1 and 2 every cycle for up
to 9 mo. Intermediate-dose regimens consisted of 5-wk
treatment cycles with IL-2 (18 mIU  1) 5 d/wk for 3 wk,
followed by 2 wk off-treatment, for up to four cycles. Histamine
dihydrochloride 1 mg  2 for 5 d/wk was added in conjunction
with IL-2 in some patients (Table 1). The reasons for not
participating in the present study were non–clear cell histology
(n = 12), lack of informed consent (n = 19), not evaluable for
response (n = 4), fine needle biopsies only (n = 2), or
insufficient tumor tissue or necrosis (n = 25). Among patients
with clear cell histology, a total of 58 patients had a baseline
biopsy. Out of these patients, 42 patients also had an on-
treatment biopsy. The reasons for not having an on-treatment
biopsy were withdrawal of informed consent or insufficient
tumor tissue. Core needle biopsies (18G cutting needle) were
collected by standard ultrasound-guided procedures. The
biopsies were obtained before treatment (baseline) and within
the first 2 mo of treatment at predefined time points according
to the treatment schedule (on treatment). The first and second
biopsies were always taken from the same tumor site, either the
primary tumor or a metastatic lesion. Objective response was
defined according to standard WHO criteria (35). All studies
were conducted in accordance with the Helsinki declaration II
and approved by the local ethics committee and the Danish
Medical Agency.
Immunohistochemical labeling of FOXP3-positive cells. The
paraffin-embedded core needle biopsies were sectioned at 2 Am
and mounted on glass slides. Primary antibody was against
FOXP3-positive (clone 236 A/E7, dilution 1:50; Biocare
Medical). Immunohistochemistry was done using a BenchMark
XT automated stainer (Ventana Medical Systems, Inc.). Depar-
affinization, epitope retrieval, and immunostainings were done
according to the manufacturer’s instruction using Cell Condi-
tioning solutions (CC1) and the ultra-VIEW Universal DAB
detection system. Positive signals were amplified using ultra-
VIEW Copper and sections were counterstained with hematox-
ylin and bluing reagent. In each run formalin-fixed paraffin-
embedded tonsillar, pancreatic, appendix, and liver sections
were included as positive controls.
Double-stainings for FOXP3-positive/CD4-positive and
FOXP3-positive/CD25-positive were done as described above
Translational Relevance
Studies based on peripheral blood have shown FOXP3-
positive regulatory immune cells to increase during inter-
leukin-2 treatment, thereby potentially compromising a
sufficient immune response.
This translational study is based on prospectively
collected serial biopsies from patients with metastatic
clear cell renal cell carcinoma. It is the first study system-
atically assessing the baseline and on-treatment expres-
sion of FOXP3-positive regulatory immune cells in
patients before and during IL-2^ based immunotherapy.
We showed a significant absolute increase in intratumoral
FOXP3-positive regulatory cells in metastatic renal cell
carcinoma following IL-2 treatment, and also a relatively
higher increase of FOXP3-positive compared with the
increases of CD3-positive and CD8-positive immune
cells. High numbers of on-treatment FOXP3-positive cells
were correlated with poor prognosis in patients with
metastatic renal cell carcinoma. All long-term survivors
were characterized by low-baseline FOXP3-positive cells
and a modest absolute increase in FOXP3-positive cells.
Aiming at understanding the relatively low response rate
following IL-2 ^ based therapy and the need for an
improved outcome, this study shows a clear application
to the future management of patients with metastatic renal
cell carcinoma, and supports continued clinical research
in combined FOXP3-positive depletion and immunomo-
dulation.
Table 1. Patient characteristics
Characteristics Baseline (n = 58)
No (%)
Age, y
Median 60
Range 19-74
Sex
Male 42 (72)
Karnofsky performance status
100 21 (36)
90 19 (33)
80 8 (14)
70 10 (17)
MSKCC prognostic criteria
Favorable 5 (9)
Intermediate 34 (59)
Poor 19 (33)
Prior nephrectomy
Yes 21 (36)
No 37 (64)
Treatment
IL2, IFN, and histamine 11 (19)
IL2 and IFN 9 (15)
IL2 and histamine 16 (28)
IL2 22 (38)
Treatment outcome
PR 4 (7)
SD/PD 54 (93)
Biopsy specimen
Primary tumor 30 (52)
Metastatic lesion 28 (48)
Abbreviations: MSKCC, Memorial Sloan Kettering Cancer Center;
PR, partial response; SD, stable disease; PD, progressive disease.
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using horseradish peroxidase and 3,3-diaminobenzidine tetra-
hydrochloride for FOXP3-positive, and alkaline phosphatase
and Fast Red for CD4-positive and CD25-positive.
The staining and quantification of other immune cell subsets
(CD3-positive, CD4-positive, CD8-positive, CD56-positive,
CD57-positive, CD66b-positive, and macrophages) have been
reported previously (34, 36, 37).
Quantification of FOXP3-positive cells. The number of
intratumoral FOXP3-positive immune cells per mm2 was
estimated using stereological counting technique (CAST soft-
ware; ref. 38). In brief, the tumor section was encircled at the
image projected onto the computer screen. A motorized stage
controlled by the computer sampled the first counting field at
random and then moved systematically throughout the biopsy
section. The staining was very specific and only nuclear staining
of leukocytes was observed. A minimum of 40 counting frames
(4,989 Am2 each) were chosen when the biopsy size allowed,
analyzing the entire core needle biopsy. Counting frames were
considered of use when tumor cells were present in the area.
Areas including necrosis and artifacts were omitted. At a 1024
magnification a median of 81 counting frames (range, 23-112
frames), and a median area of the whole biopsy of 28% (range,
1.5-100%) was evaluated. Staining was analyzed by one
blinded observer (HKJ).
The fraction of FOXP3/CD4-positive and FOXP3/CD25-
positive cells of the total FOXP3 cells were estimated semiquan-
titatively at 400 by a senior pathologist (NM) and HKJ.
Statistical analysis. For comparisons of pretreatment and
on-treatment biopsies and correlations between the different
immune cell subtypes, nonparametric tests were used (Wil-
coxon and Spearman’s rank correlation). Comparisons between
Fig. 1. Representative examples of FOXP3-positive immunostainings (200).The images A and B are from the same patient at baseline (A) and on-treatment (B).They
illustrate the infiltration of immune cells in general and the increase of FOXP3-positive in particular. C, double-labeled FOXP3-positive CD4-positive cells.D, double-labeled
FOXP3-positive CD25-positive cells.The vast majority of the FOXP3-positive cells were CD4-positive and CD25-positive (400).
Fig. 2. The number of FOXP3-positive regulatory immune cells/mm2 at baseline
and on-treatment inmetastatic renal cell carcinoma.The crosses at baseline indicate
patients with only baseline biopsies available (16 patients). For the 42 patients
with both baseline and on-treatment biopsies, each line connects the two
corresponding values for a single patient.The difference between baseline and
on-treatment values is statistically significant (P < 0.001).
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the subgroups of patients were done using Fisher’s exact test.
Overall survival was estimated using the Kaplan-Meier method
and log rank test. Survival was measured from the day of
treatment initiation for the baseline values, and the day of the
second biopsy for the on-treatment values, to the time of death
or last follow-up. Survival status was updated on August 27,
2007. For the survival analysis, the absolute numbers of
FOXP3-positive cells at baseline and on-treatment were divided
into quartiles. The association of the number of on-treatment
FOXP3-positive cells above the 75% percentile with overall
survival was evaluated in a Cox proportional hazards regres-
sions models analysis with the Memorial Sloan Kettering
Cancer Center risk groups (poor risk group versus intermediate
and good; ref. 39). Due to the low number of cases, no further
variables were added. Statistical analyses were done using SPSS
version 11.0 (SPSS Inc.) statistical software. All tests were two-
sided, and P < 0.05 was considered statistically significant.
Results
Patient characteristics. A summary of the clinical character-
istics of the baseline population is given in Table 1. The median
survival for all 58 patients was 13 months (range, 0.5-102.7
months), and 52 of the 58 patients were dead at the time of
analysis. The median age was 60 years (range, 19-74 years) and
72% were male. Sixty-four percent of the patients had the
primary tumor in situ and 33% belonged to the Memorial Sloan
Kettering Cancer Center poor prognostic group (39). Four had
a partial response to treatment and 23 achieved stable disease.
There were no significant differences between the total
treatment population (N = 120) and the 58-patient study
group as well as the 42-patient study group (P = 0.11 and P =
0.17, respectively) with respect to well-known prognostic
factors (Memorial Sloan Kettering Cancer Center criteria;
ref. 39).
FOXP3 baseline and during treatment. An example of the
FOXP3 immunostaining is shown in Fig. 1. Fifty-five patients
(95%) had intratumoral FOXP3-positive cells present at
baseline and all 42 patients had intratumoral FOXP3-positive
cells present in the on-treatment biopsies. Comparing the
baseline and on-treatment values in the individual
patients, there was a significant difference in the number
of FOXP3-positive cells following IL-2 treatment from
23 cells/mm2 (range, 0-183 cells/mm2) in the baselines
biopsies to 89 cells/mm2 (range, 11-388 cells/mm2) in the
on-treatment biopsies (P < 0.001; Fig. 2). The relative
increase in FOXP3-positive immune cells in the individual
patients was median 4.7-fold (range, 0.3- to 231-fold). Thus,
there was a rise in 35 patients (83%) and a decrease in only
7 patients (17%). Interestingly, the absolute increase in
FOXP3-positive cells during treatment was inversely correlat-
ed to the presence of FOXP3-positive cells before treatment
(Spearman’s U = -0.45; P = 0.003), and all six long-term
survivors (alive z59 months) were characterized by low-
baseline FOXP3-positive cells and a modest absolute rise in
FOXP3-positive cells (Fig. 3).
There was no impact of biopsy site (primary tumor or
metastases; P = 0.61) or whether the treatment comprised
intermediate- or low-dose IL-2 (P = 0.56), IFN-a containing
regimens (P = 0.56), or histamine (P = 0.89) on the absolute
numbers of FOXP3-positive cells following IL-2–based treat-
ment.
Phenotypic characteristics of the FOXP3-positive cells. In
order to show the type of cells expressing FOXP3, we did
double-staining of FOXP3/CD4 and FOXP3/CD25 (Fig. 1C and
D). For these analyses, sufficient tumor samples were available
in 19 biopsies from 12 patients. Double-labeling of FOXP3-
positive and CD4-positive cells revealed a median of 90%
(range, 60-100%) of the FOXP3-positive cells to be CD4-
positive. A median of 70% (range, 50-90%) of the FOXP3-
positive cells were positive for CD25. No difference in the cell
fraction of double-positive cells following IL-2 treatment
compared with baseline was observed.
Correlation to other intratumoral immune cells. We have
previously reported on tumor infiltration of CD3-positive T
cells, CD4-positive T cells, CD8-positive T cells, CD56-positive
NK cells, CD57-positive NK cells, CD66b-positive neutrophils,
and macrophages in these patients, both baseline and during
therapy (36, 37). Analyses of the correlations between FOXP3-
positive and immune cell subsets revealed a significant positive
correlation at baseline with CD3-positive, CD4-positive, CD8-
positive, and CD57-positive cells (P < 0.05). On-treatment,
there were significant positive correlations between FOXP3-
positive and CD3-positive, CD4-positive, CD8-positive, and
CD66b-positive cells (Table 2).
The increase in numbers of FOXP3-positive cells were
compared with the changes in CD3-positive and CD8-positive
immune cells. At baseline, the median FOXP3/CD3 ratio was
0.12 (range, 0-11.1), whereas the on-treatment median value
was 0.26 (range, 0.02-9.6). Similarly, the baseline median
FOXP3/CD8 ratio was 0.21 (range, 0-5.8), and on-treatment
0.62 (range, 0.03-9.6). Both differences were statistically
significant with increasing percentages being most prominent
(P = 0.004 and P = 0.001, respectively).
Correlation between FOXP3-positive cells and response.
There was no impact of baseline FOXP3-positive densities
when comparing responders and nonresponders (P = 0.8), or
comparing progressive disease and non–progressive disease
patients (P = 0.3). In addition, no impact of the on-treatment
Fig. 3. The scatter plot shows the absolute increase in FOXP3-positive cells
following IL-2^ based treatment as a function of baseline values in the 42 patients.
The increase in FOXP3-positive cells inversely correlated with the presence of
FOXP3-positive cells at baseline. Open circles, patients alive (z59 mo); closed
circles, deceased patients.
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densities on response or progression of disease was seen
(P = 0.9 and P = 0.2, respectively).
FOXP3-positive cells and survival. The impact of the baseline
and on-treatment FOXP3-positive cells on survival following
IL-2–based therapy was explored by Kaplan-Meier curves and
log rank test dividing the patients into quartiles. There was no
difference in overall survival probability when comparing the
upper quartile with the lower three quartiles in the baseline
group of patients (n = 58; P = 0.5). For the on-treatment
biopsies (n = 42), however, a significant difference was
observed comparing patients above the 75% percentiles with
the remaining lowest quartiles (P = 0.04; Fig. 4). Thus, all
patients achieving high numbers (>180 cells/mm2) of on-
treatment FOXP3-positive intratumoral regulatory immune
cells were dead within 22 months (n = 11), whereas patients
with low numbers (<180 cells/mm2) of FOXP3-positive cells
(n = 31) had a 5-year survival rate of 19%. In the multivariate
analysis, the difference remained statistically significant (hazard
ratio, 2.2; confidence interval, 1.03-4.5; P = 0.043).
Discussion
The present study is to our knowledge the first study to
evaluate the clinical relevance of IL-2–induced intratumoral
FOXP3-positive regulatory immune cells in patients with
metastatic renal cell carcinoma. The frequency and absolute
number of intratumoral FOXP3-positive cells was significantly
increased following IL-2–based therapy, and high numbers of
on-treatment FOXP3-positive cells correlated with poor prog-
nosis in patients with metastatic renal cell carcinoma. These
results are consistent with and extend previous data based on
circulating FOXP3-positive cells in blood samples from patients
with metastatic renal cell carcinoma treated with IL-2.
The impact of IL-2 on peripheral circulating FOXP3-positive
cells has previously been shown in different tumor types. In
pediatric sarcoma patients receiving either IL-2 or no IL-2,
Zhang et al. explored regulatory T cells and observed IL-2
recipients to have significantly higher FOXP3-positive expres-
sion (33). Similarly, in patients with malignant melanoma and
renal cell carcinoma, Ahmadzadeh et al. showed high-dose
bolus IL-2 to significantly increase the proportion of CD4-
positive CD25-positive T cells expressing FOXP3-positive in the
peripheral blood (29). Two other studies testing high-dose IL-2
schedules showed similar results (30, 31). Despite the s.c.
administration and the low and intermediate levels of IL-2 used
in the present study, our intratumoral data agree with existing
peripheral blood data obtained in these high dose studies. The
impact of high-dose IL-2 on intratumoral FOXP3 cells needs to
be clarified.
In ovarian cancer, evidence of IL-2 as a promoter of
regulatory T-cell tumor infiltration was reported by Wei et al.,
who observed that regulatory T cells efficiently migrated with
ovarian tumor ascites following IL-2 treatment, suggesting that
specific cytokines in the microenvironment attract regulatory
T cells in response to IL-2 treatment (32). In addition, the IL-2–
induced regulatory T cell proliferation was negatively influ-
enced by the existing regulatory T cells (32). This is consistent
with our results, as we observed the increase in FOXP3-positive
cells inversely correlating with the number of FOXP3-positive
cells at baseline. In other words, FOXP3-positive cells may have
a self-inhibitory effect.
To our knowledge, no literature regarding the effect of IFN on
FOXP3-positive cells has been published. Consistent with this
we observed identical on-treatment FOXP3-positive cell densi-
ties in patients treated with or without IFN-containing
regimens.
IL-2 functions entirely through activation of the patient’s
endogenous immune system, and orchestration of an effective
antitumor immune response is prerequisite for durable tumor
eradication. However, the exact mechanism of action is unclear.
Thus, although IL-2–based immunotherapy may induce
durable tumor regression in some patients with metastatic
renal cell carcinoma, it also seems that treatment with IL-2 may
compromise the establishment of an effective antitumor
immune response in some patients by the development of
reciprocal alterations of immunoregulatory cells (31).
In the present study, the increase in FOXP3-positive density
following IL-2 treatment was associated with poor overall
survival. It was, however, most prominent in patients having
levels of FOXP3-positive cells above the 75% percentile,
suggesting that the threshold for immune suppression is
relatively high. We observed that the number of FOXP3-
positive cells increased more than the number of effector T cells
following IL-2 administration as the FOXP3/CD8-positive ratio
increased from 0.21 to 0.62. This indicates an existence of a
balance between FOXP3-positive cells and CD3-positive or
CD8-positive cells causing either tumor immune response or
tolerance. The association between IL-2– induced rise in
FOXP3-positive cells and overall survival needs further inves-
tigation.
Table 2. Correlations between intratumoral FOXP3-positive cells and intratumoral T-cells, NK cells,
neutrophils, and macrophages at baseline and on-treatment
Cell type Baseline FOXP3 positive On-treatment FOXP3 positive
Spearman’s R P Biopsies evaluated Spearman’s R P Biopsies evaluated
CD3-positive T cells 0.50 <0.001 54 0.37 0.02 42
CD4-positive T cells 0.32 0.02 57 0.43 0.005 42
CD8-positive T cells 0.58 <0.001 57 0.57 <0.001 41
CD57-positive NK cells 0.46 <0.001 56 0.20 0.2 42
CD56-positive NK cells 0.22 0.1 57 0.07 0.66 41
CD66b-positive Neutrophils 0.16 0.23 57 0.34 0.03 42
Macrophages 0.08 0.57 57 0.13 0.43 41
NOTE: Missing values are due to nonevaluable sections.
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For this FOXP3 analysis, we only had tumor material
available and were therefore not able to assess peripheral
blood FOXP3-positive cells. Griffths et al. compared intra-
tumoral and peripheral blood FOXP3-positive cells in five renal
cell carcinoma patients and observed a positive correlation
between these two compartments (17). Indeed, Griffiths et al.
observed the highest frequency in the tumor site, consistent
with the high frequencies observed in the present study. This
suggests similar frequencies in the two compartments, but
needs to be confirmed in a considerable larger material.
Baseline FOXP3-positive tumor-infiltrating immune cells
were not prognostic for survival in the current study. This
observation concurs with a study by Siddiqui et al. of 170
clear cell renal cell carcinoma tumor samples, in which the
presence of CD4-positive CD25-positive FOXP3-negative cells,
rather than FOXP3-positive cells, was related to cancer-specific
survival (16). The Siddiqui study population involved 15%
stage IV patients, and only a minority of these patients (21%)
had FOXP3-positive cells present, whereas our cohort exclu-
sively contained patients with metastatic disease and 95% had
FOXP3-positive cells present at baseline. This different preva-
lence of FOXP3-positive cells could reflect the use of two
different antibodies, frozen tissue technique, and differences in
case mix.
We evaluated the phenotype of the FOXP3-positive cells
using double-labeling with CD4-positive and CD25-positive,
respectively. The vast majority of the FOXP3-positive cells were
CD4 positive and CD25 positive, both at baseline and
following IL-2. This is consistent with several other studies
having revealed similar phenotypic and functional character-
istics regardless of the induction stimulus, at least regarding
peripheral, circulating FOXP3-positive cells (29, 30, 33). Also,
the antibody used in the present study has previously been
shown to specifically label FOXP3-positive cells of regulatory,
suppressor subtype (7, 40).
The findings in the current study have improved our
understanding of the complexity following IL-2 administration,
and have also emphasized the vital therapeutic option of
reversal tumor-mediated immunosuppression by eliminating
regulatory T cells. It should be noted that all long-term
survivors in our study were characterized by low-baseline
FOXP3-positive cells and a modest absolute increase in FOXP3-
positive cells. Promising preclinical findings inhibiting and
depleting FOXP3-positive cells have been investigated using
approaches such as vascular endothelial growth factor blockade
(41), local CTL Antigen-4 blockade, systemic regulatory T cell
depletion (by cyclophosphamide or anti-CD25 antibodies; refs.
42, 43), and vaccination against FOXP3-positive cells (44).
Most of these approaches have led to tumor regression and
improved survival of tumor-bearing mice. However, translating
these results into the clinical setting has so far been without the
desired improvement in response rate and survival, despite the
ability to reduce the number of regulatory T cells in the tumor
(45, 46).
In conclusion, the present study showed that intratumoral
regulatory FOXP3-positive cells increased during IL-2 treatment
and adversely correlated with overall survival. These results
support further clinical studies depleting regulatory T cells in
combination with IL-2 in metastatic renal cell carcinoma.
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Fig. 4. Survival curves showing overall survival probability based on separation
of the patients into two groups above and below the 75% percentile of the
on-treatment FOXP3-positive value. Solid line, patients in the fourth quartile (n = 11;
events = 11); dotted line, remaining three quartiles (n = 31; events = 25).
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